Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and longer-term studies are needed to establish safety and efficacy. METHODS: We conducted a randomized trial involving 2341 patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or more and were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with an acceptable side-effect profile), with or without other lipid-lowering therapy. Patients were randomly assigned in a 2:1 ratio to receive alirocumab (150 mg) or placebo as a 1-ml subcutaneous injection every 2 weeks for 78 weeks. The primary efficacy end point was the percentage change in calculated LDL cholesterol level from baseline to week 24. RESULTS: At week 24, the difference between the alirocumab and placebo groups in the mean percentage change from baseline in calculated LDL cholesterol level was -62 percentage points (P<0.001); the treatment effect remained consistent over a period of 78 weeks. The alirocumab group, as compared with the placebo group, had higher rates of injection-site reactions (5.9% vs. 4.2%), myalgia (5.4% vs. 2.9%), neurocognitive events (1.2% vs. 0.5%), and ophthalmologic events (2.9% vs. 1.9%). In a post hoc analysis, the rate of major adverse cardiovascular events (death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) was lower with alirocumab than with placebo (1.7% vs. 3.3%; hazard ratio, 0.52; 95% confidence interval, 0.31 to 0.90; nominal P=0.02). CONCLUSIONS: Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels. In a post hoc analysis, there was evidence of a reduction in the rate of cardiovascular events with alirocumab. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY LONG TERM ClinicalTrials.gov number, NCT01507831.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50-70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the initial trials of these drugs, the incidence of neurocognitive adverse events (including delirium, cognitive and attentional disturbances, dementia, thought and perceptual disturbances, and psychiatric disorders) was very low (<1%) but slightly higher albeit non-significantly in the treated groups compared with placebo (0.9% vs. 0.3% for evolocumab) (81) (1.2% vs. 0.5% for alirocumab) (82).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“alirocumab, a PCSK9 monoclonal antibody in clinical use (Robinson et al., 2015)”
From γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor (2018) · cites this paper as Robinson et al., 2015
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Data from the GLAGOV, ODYSSEY COMBO I and ODYSSEY LONG TERM trials show greater efficacy of PCSK9 inhibitors in patients with prior CVD (or myocardial infarction) in terms of LDL-C and percent atheroma volume [86–88].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [88]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The beneficial effect of ezetimibe is also supported by genetic studies of mutations in NPC1L1; naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD [55,269,270].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [270]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Cited by
Items 401–500 of 1,019
Daniels, S. R., Caprio, S., Chaudhari, U., Manvelian, G. Z., Baccara‐Dinet, M. T., Brunet, A., Scemama, M., Loizeau, V., & Bruckert, É. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.03.001 · Cited by 61
Self-citationPCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
Ito, M. K., & Santos, R. D. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.766 · Cited by 59
Picard, C., Poirier, A., Bélanger, S., Labonté, A., Auld, D., Poirier, J., & on behalf of the PREVENT-AD Research Group (2019) · PLOS ONE · doi:10.1371/journal.pone.0220254 · Cited by 59
Current progress in the development of prophylactic and therapeutic vaccines
Li, T., Qian, C., Gu, Y., Zhang, J., Li, S., & Xia, N. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2230-4 · Cited by 63
“evolocumab, which were approved by the FDA in 2015, and provided solid clinical evidence for the development of PCSK9 vaccines (Jones, 2015; Robinson et al., 2015).”
BackgroundNew Drugs for Treating Dyslipidemia: Beyond Statins
Ahn, C. H., & Choi, S. H. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.2.87 · Cited by 69
New Era of Lipid-Lowering Drugs
Barter, P. J., & Rye, K. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012203 · Cited by 65
Bertoluci, M. C., Moreira, R. O., Faludi, A. Á., Izar, M. C. D. O., Schaan, B. D., Valério, C. M., Bertolami, M. C., Chacra, A. P. M., Malachias, M. V. B., Vencio, S. A. C., et al. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0251-z · Cited by 69
“In post hoc cardiovascular safety analyses of alirocumab and evolocumab added to statins with or without other lipid-lowering therapies, mean LDL-c levels of 48 mg/dL were associated with statistically significant relative risk reductions of 48–53% in major CLAD events [107, 108].”
BackgroundDevelopment of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia
Ahamad, S., Mathew, S., Khan, W. A., & Mohanan, K. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.014 · Cited by 60
Sathiyakumar, V., Park, J., Quispe, R., Elshazly, M. B., Michos, E. D., Banach, M., Toth, P. P., Whelton, S. P., Blumenthal, R. S., Jones, S. R., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032463 · Cited by 58
Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes
Khavandi, M., Duarte, F., Ginsberg, H. N., & Reyes‐Soffer, G. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0818-1 · Cited by 66
Momtazi‐Borojeni, A. A., Jaafari, M. R., Afshar, M., Banach, M., & Sahebkar, A. (2021) · Archives of Medical Science · doi:10.5114/aoms/133885 · Cited by 63
Gene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects
Cao, G., Xuan, X., Zhang, R., Hu, J. H., & Dong, H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.760140 · Cited by 61
“The monoclonal antibody targeted PCSK9 has been investigated in ODYSSEY trial (alirocumab) (89), FOURIER trial (evolocumab) (90) and SPIRE trials (bococizumab) (91).”
BackgroundPCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives
Nicholls, S. J. (2023) · Kardiologia Polska · doi:10.33963/kp.a2023.0030 · Cited by 60
Precision medicine, genomics and drug discovery: Table 1.
Cardon, L. R., & Harris, T. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw246 · Cited by 65
Mundal, L. J., Igland, J., Ose, L., Holven, K. B., Veierød, M. B., Leren, T. P., & Retterstøl, K. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316676135 · Cited by 60
“For those who initiate treatment late in life, the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors may be of particular importance for aggressive treatment.(23)”
BackgroundHess, G. P., Natarajan, P., Faridi, K. F., Fievitz, A., Valsdottir, L. R., & Yeh, R. W. (2017) · Circulation · doi:10.1161/circulationaha.117.028430 · Cited by 66
Swerdlow, D. I., Rider, D. A., Yavari, A., Lindholm, M., Campion, G., & Nissen, S. E. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab100 · Cited by 62
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide
Navar, A. M., Mikhailova, E., Catapano, A. L., Banka, P., Blom, D. J., Cadena, A., Kourpanidis, S., Lepor, N. E., Tsukamoto, K., Mendizabal, G., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2511002 · Cited by 57
Self-citationLipids, blood pressure and kidney update 2015
Banach, M., Aronow, W. S., Șerban, M.-C., Rysz, J., Voroneanu, L. E., & Covic, A. C. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0169-0 · Cited by 63
“001) after 24 weeks of therapy [14].”
BackgroundInfluentialRobinson, J. G., Jayanna, M. B., Brown, A. S., Aspry, K. E., Orringer, C. E., Gill, E. A., Goldberg, A. C., Jones, L. K., Maki, K. C., Dixon, D. L., et al. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.05.005 · Cited by 58
Self-citationGu, J., Sanchez, R. J., Chauhan, A., Fazio, S., & Wong, N. D. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100336 · Cited by 54
“Since 2014, other novel LLTs that provide powerful LDL-C lowering have come to market, including two proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, which lower LDL-C levels by up to 60% and reduce CV events among patients with ASCVD on statin therapy[3,4,7].”
BackgroundTherapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future
Weber, C., Badimón, L., Mach, F., & van der Vorst, E. P. C. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-10-0814 · Cited by 60
Milionis, H. J., Ntaios, G., Korompoki, E., Vemmos, K. N., & Michel, P. (2019) · International Journal of Stroke · doi:10.1177/1747493019873594 · Cited by 61
Guo, Y., Yan, B., Gui, Y., Tang, Z., Tai, S., Zhou, S., & Zheng, X. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30025 · Cited by 62
“PCSK9 inhibitors significantly reduced systemic LDL‐c levels in several large clinical trials, including ODYSSEY (Robinson et al., 2015; Schwartz et al., 2018; Szarek et al., 2019) and FOURIER (further cardiovascular outcomes research with PCSK9 inhibition subjects with elevated risk; Bonaca et…”
BackgroundInfluentialGinsberg, H. N., Rosenson, R. S., Hovingh, G. K., Letierce, A., Samuel, R., Poulouin, Y., & Cannon, C. P. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100148 · Cited by 60
Toth, P. P., Bray, S., Villa, G., Palagashvili, T., Sattar, N., Stroes, E. S. G., & Worth, G. M. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025551 · Cited by 56
Self-citationPleiotropic Effects of PCSK-9 Inhibitors
Basiak, M., Kosowski, M., Cyrnek, M., Bułdak, Ł., Maligłówka, M., Machnik, G., & Okopień, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063144 · Cited by 60
Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment
Ahamad, S., & Bhat, S. A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01290 · Cited by 58
The Success Story of LDL Cholesterol Lowering
Pedersen, T. R. (2016) · Circulation Research · doi:10.1161/circresaha.115.306297 · Cited by 56
Future of the Prevention and Treatment of Coronary Artery Disease
Steg, P. G., & Ducrocq, G. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0266 · Cited by 61
MicroRNA-30c Mimic Mitigates Hypercholesterolemia and Atherosclerosis in Mice
Irani, S., Pan, X., Peck, B. C. E., Iqbal, J., Sethupathy, P., & Hussain, M. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.728451 · Cited by 59
Wang, X., & Musunuru, K. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.05.008 · Cited by 58
“In 2015, the efficacy of alirocumab and evolocumab, 2 human monoclonal antibody-based drugs that target proprotein convertase subtilisin/kexin type 9 (PCSK9), was confirmed with respect to the reduction of LDL-C levels in patients (2,3).”
BackgroundFang, S., Yarmolinsky, J., Gill, D., Bull, C. J., Perks, C. M., the PRACTICAL Consortium, Davey Smith, G., Gaunt, T. R., & Richardson, T. G. (2023) · PLOS Medicine · doi:10.1371/journal.pmed.1003988 · Cited by 55
“With excellent efficacy and safety profiles, 2 monoclonal antibodies against PCSK9 have been developed to lower elevated LDL-c levels and subsequently help prevent coronary heart disease (CHD) [68,69].”
BackgroundResultInfluentialAdvances in treatment of Dyslipidemia
Dybiec, J., Baran, W., Dąbek, B., Fularski, P., Młynarska, E., Radzioch, E., Rysz, J., & Franczyk, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713288 · Cited by 55
“The ad inistration of this drug resulted in a decrease in LDL-C by as uch as 61% after 24 weeks and over 52% after more than 78 weeks [51,53].”
BackgroundNelson, C. P., Lai, F. Y., Nath, M., Ye, S., Webb, T. R., Schunkert, H., & Samani, N. J. (2019) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.118.002196 · Cited by 55
Novel Therapeutical Approaches to Managing Atherosclerotic Risk
Giglio, R. V., Stoian, A. P., Al‐Rasadi, K., Banach, M., Patti, A. M., Ciaccio, M., Rizvi, A. A., & Rizzo, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094633 · Cited by 57
Dyslipidaemia in the Middle East: Current status and a call for action
Al‐Rasadi, K., Almahmeed, W. A., AlHabib, K. F., Abifadel, M., Farhan, H. A., Alsifri, S. N., Jambart, S., Zubaid, M., Awan, Z. A., Al-Waili, K., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.925 · Cited by 58
Future perspectives of the pharmacological management of diabetic dyslipidemia
Patti, A. M., Giglio, R. V., Παπάνας, Ν., Rizzo, M., & Rizvi, A. A. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1567328 · Cited by 58
Grimaudo, S., Bartesaghi, S., Rametta, R., Marra, F., Mancina, R. M., Pihlajamäki, J., Kakol‐Palm, D., Andréasson, A., Dongiovanni, P., Fracanzani, A. L., et al. (2020) · Liver International · doi:10.1111/liv.14711 · Cited by 54
Ischemic Event Rates in Very-High-Risk Adults
Colantonio, L. D., Shannon, E., Orroth, K. K., Zaha, R. L., Jackson, E. A., Rosenson, R. S., Exter, J., Mues, K. E., & Muntner, P. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.09.025 · Cited by 65
microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
Dong, J., He, M., Li, J., Pessentheiner, A., Wang, C., Zhang, J., Sun, Y., Wang, W.-T., Zhang, Y., Liu, J., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.143812 · Cited by 53
A review of PCSK9 inhibition and its effects beyond LDL receptors
Dixon, D. L., Trankle, C., Buckley, L., Parod, E., Carbone, S., Van Tassell, B. W., & Abbate, A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.07.004 · Cited by 53
“70 mg/dL on maximally tolerated statin.(13) Participants were randomized in a 2:1 fashion to alirocumab or placebo in addition to background statin therapy.”
Hartgers, M. L., Defesche, J. C., Langslet, G., Hopkins, P. N., Kastelein, J. J. P., Baccara‐Dinet, M. T., Seiz, W., Hamon, S., Banerjee, P., & Stefanutti, C. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.12.008 · Cited by 53
Self-citationFeng, Z., Li, X., Tong, W. K., He, Q., Zhu, X. L., Xiang, X., & Tang, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.894685 · Cited by 53
“The muscle-related AE signals were mainly manifested as back pain, myalgia, pain in extremity, arthralgia, and muscle spasms, which was consistent with evidence from previous clinical trials (Robinson et al., 2015; Moriarty et al., 2020).”
ResultThe PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
Seidah, N. G. (2017) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2017.2 · Cited by 51
Managing risks in drug discovery: reproducibility of published findings
Kannt, A., & Wieland, T. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1216-8 · Cited by 57
PCSK9 regulates the chemokine receptor CCR2 on monocytes
Grune, J., Meýborg, H., Bezhaeva, T., Kappert, K., Hillmeister, P., Kintscher, U., Pieske, B. M., & Stawowy, P. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.02.085 · Cited by 55
Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain
Villa, G., Löthgren, M., Kutikova, L., Lindgren, P., Gandra, S. R., Fonarow, G. C., Sorio, F., Masana, L., Bayés‐Genís, A., & van Hout, B. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.02.011 · Cited by 58
Defesche, J. C., Stefanutti, C., Langslet, G., Hopkins, P. N., Seiz, W., Baccara‐Dinet, M. T., Hamon, S., Banerjee, P., & Kastelein, J. J. P. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.08.016 · Cited by 56
Self-citationA Meta-Analysis of the Effect of PCSK9-Monoclonal Antibodies on Circulating Lipoprotein (a) Levels
Cao, Y., Liu, H., Li, S., & Li, J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0303-2 · Cited by 55
Brouwers, M. C. G. J., Simons, N., Stehouwer, C. D. A., Koek, G. H., Schaper, N. C., & Isaacs, A. J. (2019) · Hepatology Communications · doi:10.1002/hep4.1319 · Cited by 53
Clinical Pharmacology of Statins: an Update
Ferri, N., & Corsini, A. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00844-w · Cited by 56
Safety and Tolerability of PCSK9 Inhibitors: Current Insights
Kosmas, C. E., Skavdis, A., Sourlas, A., Papakonstantinou, E. J., Genao, E. P., Uceta, R. E., & Guzman, E. (2020) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s288831 · Cited by 58
Current Options and Future Perspectives in the Treatment of Dyslipidemia
Muscoli, S., Ifrim, M., Russo, M., Candido, F., Sanseviero, A., Milite, M., Luozzo, M. D., Marchei, M., & Sangiorgi, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164716 · Cited by 56
“placebo in 2341 patients at high risk for CVD who were already receiving the maximum tolerated dose of statins [13].”
BackgroundMethodInfluentialKim, Y., Landstrom, A. P., Shah, S. H., Wu, J. C., & Seidman, C. E. (2024) · Circulation · doi:10.1161/cir.0000000000001296 · Cited by 91
Li, J., Li, S., Zhang, Y., Xu, R., Guo, Y., Zhu, C., Wu, N., Qing, P., Gao, Y., Sun, J., et al. (2015) · Medicine · doi:10.1097/md.0000000000002426 · Cited by 56
Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis
Bertrand, M.-J., & Tardif, J. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1269743 · Cited by 59
“Although exploratory analyses have already suggested that these agents may reduce CV event rates [71,81], the effects of Table 1.”
BackgroundResultEvaluating bempedoic acid for the treatment of hyperlipidaemia
Penson, P. E., McGowan, M. P., & Banach, M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1280458 · Cited by 53
“The ODYSSEY-LONG TERM trial, which recruited participants with heterozygous familial hypercholesterolemia (HeFH), CHD or a risk equivalent, demonstrated substantial reductions in LDL-C after treatment with alirocumab, a monoclonal antibody inhibitor of PCSK9 protein, when used with a statin [8, 9].”
Saeed, A., & Ballantyne, C. M. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.007 · Cited by 51
Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis
Tummala, R., Gupta, M., Devanabanda, A. R., Bandyopadhyay, D., Aronow, W. S., Ray, K. K., Mamas, M. A., & Ghosh, R. K. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2059559 · Cited by 56
Lee, S. J., Kim, S.-E., Go, T., Kang, D. R., Jeon, H.-S., Kim, Y., Cho, D., Park, Y. J., Lee, J., Lee, J., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad036 · Cited by 54
Toth, P. P., Hamon, S., Jones, S. R., Martin, S. S., Joshi, P. H., Kulkarni, K. R., Banerjee, P., Hanotin, C., Roth, E. M., & McKenney, J. M. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0197-4 · Cited by 52
Kohli, P., Ganz, P., Ma, Y., Scherzer, R., Hur, S., Weigel, B., Grünfeld, C., Deeks, S. G., Wasserman, S. M., Scott, R. C., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002683 · Cited by 52
“It has also been shown to improve cardiovascular outcomes in uninfected individuals in preliminary studies.(20,21) Because of their favorable safety profile, lack of drug–drug interactions with antiretroviral or HCV medications, and absence of hepatic toxicity, PCSK9 antibody inhibitors may be an advantageous lipid-lo…”
Time to ditch HDL-C as a measure of HDL function?
Ronsein, G. E., & Heinecke, J. W. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000446 · Cited by 52
“Recently, therapies with antibodies against proprotein convertase subtilisin–kexin type 9 (PCSK9), an enzyme that attaches and internalizes LDL receptors into lysosomes for degradation, were able to reduce LDL-C levels beyond those promoted by statins or any other lipid lowering treatment [2,3].”
Janik, M. J., Urbach, D. V., van Nieuwenhuizen, E., Zhao, J., Yellin, O., Baccara-Dinet, M. T., Pordy, R., & Manvelian, G. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.06.913 · Cited by 51
Self-citationLow LDL cholesterol by PCSK9 variation reduces cardiovascular mortality
Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.517 · Cited by 51
Update on the laboratory investigation of dyslipidemias
Ramasamy, I. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.01.015 · Cited by 50
Leiter, L. A., Zamorano, J. L., Bujas‐Bobanovic, M., Louie, M. J., Lecorps, G., Cannon, C. P., & Handelsman, Y. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12909 · Cited by 50
“0% with DM, n = 223), alirocumab was associated with average reductions in LDL-C of 49% with alirocumab 75 mg/150 mg every 2 weeks (Q2W; 75 mg/150 mg denotes that the initial dose of 75 mg Q2W was increased to 150 mg Q2W at Week 12 depending on Week 8 LDL-C), and 61% with alirocumab 150 mg Q2W.(6,7) In the 104-week, P…”
BackgroundResultInfluentialDyslipidemia management update
Chang, Y., & Robidoux, J. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.04.005 · Cited by 55
Genome editing in large animal models
Maynard, L. H., Humbert, O., Peterson, C. W., & Kiem, H. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.026 · Cited by 51
PCSK9 inhibitors in the prevention of cardiovascular disease
Latimer, J., Batty, J. A., Neely, R. D. G., & Kunadian, V. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1364-1 · Cited by 54
“term safety and tolerability of alirocumab in 2341 patients with either: (i) HeFH, with or without manifestations of CVD, or (ii) primary hypercholesterolemia and coronary artery disease, with LDL-C inadequately controlled despite maximally-tolerated lipid-modifying pharmacotherapy (44 % received a high-intensity stat…”
BackgroundAfshar, M. S., Kamstrup, P. R., Williams, K., Sniderman, A. D., Nordestgaard, B. G., & Thanassoulis, G. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308271 · Cited by 51
Accuracy of low-density lipoprotein cholesterol estimation at very low levels
Quispe, R., Hendrani, A. D., Elshazly, M. B., Michos, E. D., McEvoy, J. W., Blaha, M. J., Banach, M., Kulkarni, K. R., Toth, P. P., Coresh, J., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0852-2 · Cited by 53
Mandraffino, G., Scicali, R., Rodríguez‐Carrio, J., Savarino, F., Mamone, F., Scuruchi, M., Cinquegrani, M., Imbalzano, E., Pino, A. D., Piro, S., et al. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.01.015 · Cited by 52
Existing and emerging therapies for the treatment of familial hypercholesterolemia
Rosenson, R. S. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100060 · Cited by 51
“Inhibitors of PCSK9i in HeFH and HoFH patients Trial Study Population Sample Size Therapy Design Baseline Characteristics of Heterozygous/Homozygous Patients Major Outcome Inhibitors of PCSK9i in HeFH patients ODYSSEY FH I and FH II (39) Adults with HeFH (39.9% genotyped, 59.8% clinical criteria in alirocumab group) L…”
BackgroundMethodInfluentialPCSK9 in metabolism and diseases
Ajoolabady, A., Pratico, D., Mazidi, M., Davies, I. G., Lip, G. Y. H., Seidah, N., Libby, P., Kroemer, G., & Ren, J. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156064 · Cited by 49
Soran, H., Schofield, J. D., Adam, S., & Durrington, P. N. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000318 · Cited by 49
“In two separate studies, in a post hoc and an exploratory analysis compared with placebo, LDL-C lowering with alirocumab and evolocumab therapy was associated with a significant reduction in the rate of cardiovascular events in patients receiving treatment with statins at the maximum tolerated dose [78,79].”
Sex difference in circulating PCSK9 and its clinical implications
Jia, F., Fei, S.-F., Tong, D.-B., Xue, C., & Li, J.-J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.953845 · Cited by 40
“PCSK9 inhibitors could lead to significant LDL-C reductions in high-risk patients, and they have shown a favorable safety profile in recent clinical trials (Robinson et al., 2015; Sabatine et al., 2017).”
BackgroundTargeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
Banerjee, Y., Santos, R. D., Al‐Rasadi, K., & Rizzo, M. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.018 · Cited by 50
“Alirocumab (trade name Praluent) was approved in the USA by the FDA in July 2015 [3], whereas evolocumab (trade name Repatha) was approved in Europe by the European Commission also in July 2015 [4].”
BackgroundTaranto, M. D. D., Benito‐Vicente, A., Giacobbe, C., Uribe, K. B., Rubba, P., Etxebarria, A., Guardamagna, O., Gentile, M., Martín, C., & Fortunato, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-15543-x · Cited by 54
Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
Dijk, W., May, C. L., & Cariou, B. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.03.013 · Cited by 53
PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?
Mannarino, M. R., Sahebkar, A., Bianconi, V., Serban, M.-C., Banach, M., & Pirro, M. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.05.012 · Cited by 48
An Efficient Method to Generate Monoclonal Antibodies from Human B Cells
Guthmiller, J. J., Dugan, H. L., Neu, K. E., Lan, L. Y.-L., & Wilson, P. C. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8958-4_5 · Cited by 49
Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data
Strilchuk, L. M., Fogacci, F., & Cicero, A. F. G. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1620730 · Cited by 51
“mologic events, and changes in transaminase and creatine kinase concentrations [60].”
BackgroundAnti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice
Schuster, S., Rubil, S., Endres, M., Princen, H. M. G., Boeckel, J., Winter, K., Werner, C. M., & Laufs, U. (2019) · Scientific Reports · doi:10.1038/s41598-019-47242-0 · Cited by 52
Han, Y., Chen, J.-Y., Chopra, V., Zhang, S., Su, G., Ma, C., Huang, Z., Ma, Y., Yao, Z., Yuan, Z., et al. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.10.015 · Cited by 50
Meta‐analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD
Talasaz, A. H., Ho, A. (., Bhatty, F., Koenig, R. A., Dixon, D. L., Baker, W. L., & Van Tassell, B. W. (2021) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2635 · Cited by 48
Yadav, K., Sharma, M., & Ferdinand, K. C. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.05.006 · Cited by 54
Rosei, E. A., & Salvetti, M. (2016) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-016-0155-2 · Cited by 54
Vaccination against atherosclerosis
Kobiyama, K., Saigusa, R., & Ley, K. F. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.02.008 · Cited by 50
Ascaso, J. F., Civeira, F., Guijarro, C., López‐Miranda, J., Masana, L., Mostaza, J. M., Pedro‐Botet, J., Pintó, X., & Valdivielso, P. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.04.002 · Cited by 51
Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future
Chait, A., & Eckel, R. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3940 · Cited by 54
Garwood, C. L., Cabral, K. P., Brown, R., & Dixon, D. L. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4635 · Cited by 48
Pott, J., Schlegel, V., Teren, A., Horn, K., Kirsten, H., Blücher, C., Kratzsch, J., Loeffler, M., Thiery, J., Burkhardt, R., et al. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.117.001992 · Cited by 51
PCSK9: from biology to clinical applications
Blanchard, V., Khantalin, I., Ramin-Mangata, S., Chémello, K., Nativel, B., & Lambert, G. (2019) · Pathology · doi:10.1016/j.pathol.2018.10.012 · Cited by 43
Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates
Reynolds, V. W., Chinn, M. E., Jolly, J. A., Kelley, T. N., Peter, M. E., Choi, L., Nwosu, S., Leon, B. G. C., & Zuckerman, A. D. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.01.003 · Cited by 47
PCSK9 inhibitors and cardiovascular outcomes
Steffens, D., Bramlage, P., Scheeff, C., Kasner, M., Hassanein, A., Friebel, J., & Rauch-Kröhnert, U. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1677604 · Cited by 43
“the long-term studies with alirocumab [46]; however, metaanalysis of data from 14 phase 2 or 3 trials of up to 104 weeks’”
Backgrounddi Mauro, G., Zinzi, A., Scavone, C., Mascolo, A., Gaio, M., Sportiello, L., Ferrajolo, C., Rafaniello, C., Rossi, F., & Capuano, A. (2020) · Drug Safety · doi:10.1007/s40264-020-01021-3 · Cited by 49
PCSK9: A emerging participant in heart failure
Xu, Q., Zhao, Y.-M., He, N.-Q., Gao, R., Xu, W., Zhuo, X.-J., Ren, Z., Wu, C., & Liu, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114106 · Cited by 50
Björnson, E., Packard, C. J., Adiels, M., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Lundbom, J., et al. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13017 · Cited by 46
Metadata
- Authors
- Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., Koren, M. J., Lepor, N. E., Lorenzato, C., Pordy, R., Chaudhari, U., & Kastelein, J. J. P.
- Affiliations
- University of Iowa (US)
- Centre Hospitalier Universitaire de Nantes (FR)
- Université de Lille (FR)
- Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- Oslo University Hospital (NO)
- University of the Witwatersrand (ZA)
- Jacksonville Center for Clinical Research (US)
- Westside Medical Associates of Los Angeles (US)
- Sanofi (France) (FR)
- Regeneron (United States) (US)
- Sanofi (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-16
- Volume
- 372
- Issue
- 16
- Pages
- 1489-1499
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2001328643
- Semantic Scholar
- 942bcfdc93b04ccb90a2d3e1df4c7950a45e92c2
- Cited by
- 2,296
- References
- 35
- Citations by year
- 2026: 67 · 2025: 103 · 2024: 150 · 2023: 141 · 2022: 134 · 2021: 159 · 2020: 165 · 2019: 226 · 2018: 251 · 2017: 339 · 2016: 369 · 2015: 183
- FWCI
- 383.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- alirocumab, PCSK9 inhibition, LDL cholesterol lowering, statin therapy, major adverse cardiovascular events, cardiovascular risk reduction, monoclonal antibodies, injection site reactions, high-risk patients, lipid-lowering therapy
- MeSH terms
- Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.